Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

dy of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive B-cell Non Hodgkin Lymphoma (DLBCL, MCL, FL). The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP. This global, multi-center study, conducted by Janssen, has been fully accrued with 17 patients and an update on the dose escalating phase of this study was provided at ASCO 2013.With a recommended Phase II dose established, the study has enrolled additional 15 patients with newly diagnosed DLBCL and is currently in the expansion phase.
  • DBL3001: Phase III study of ibrutinib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with newly diagnosed non-germinal center B-cell subtype of DLBCL. This trial is a randomized, multi-center, double-blinded, controlled trial of ibrutinib plus R-CHOP versus R-CHOP in patients with newly diagnosed non-GCB subtype DLBCL. The primary endpoint of the study is to demonstrate a clinically significant improvement in event-free survival when compared to R-CHOP. This global study, conducted by Janssen, is not yet recruiting and Janssen plans to enroll 800 patients worldwide.
  • FL

  • FLR2002: Phase II study of ibrutinib in patients with R/R follicular lymphoma (FL). This is a multi-center, global study of ibrutinib in patients with chemoimmunotherapy-resistant FL, whose disease has relapsed from at least 2 prior lines of therapy, including at least 1 rituximab combination chemotherapy regimen. The primary endpoint of this study is objective response rate. This global study, conducted by Janssen, is recruiting and Janssen plans to enroll 110 patients.
  • WM

  • NCI STUDY: Phase II study of ibrutinib in patients with R/R WM. This is a multicenter, open label study with a primary endpoint of ORR and is currently exploring ibrutinib administration at 420 mg in patients with WM who have failed at least 1 prior thera
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
    (Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
    (Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ...
    Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
    ... , , LOUISVILLE, Colo. , Feb. ... to give a boom to body contouring practices in the ... VASER® Lipo System – comes this non-invasive ultrasound and massage ... only system that has a specific lymphatic massage component with ...
    ... , ATLANTA , ... ( Duarte, Calif. ), a leading research and treatment center ... to implement an electronic interface that links its TomoTherapy® Hi-Art® ... management system. The connection enables communication between the MOSAIQ and ...
    Cached Medicine Technology:Body Contouring Gets Refined with MedSculpt 2City of Hope Testing New Communication Link Between Cancer Therapy System and Elekta Electronic Medical Record System 2City of Hope Testing New Communication Link Between Cancer Therapy System and Elekta Electronic Medical Record System 3
    (Date:4/23/2014)... Five for-profit and non-profit organizations in Washington ... Proof of Concept grants to accelerate maturation of ... the Life Sciences Discovery Fund (LSDF) announced today. ... grant to the Washington Biotechnology & Biomedical Association ... train the next generation of entrepreneurs and help ...
    (Date:4/23/2014)... about an increase in adolescents, marijuana use following the ... relief. According to a new study at Rhode Island ... states with and without medical marijuana laws, legalizing the ... The study is published online in advance of print ... , "Any time a state considers legalizing medical marijuana, ...
    (Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
    (Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
    (Date:4/22/2014)... popular high school sport in the United States with ... researchers in the Center for Injury Research and Policy ... and describe the occurrence and distribution patterns of basketball-related ... athletic training setting among adolescents and teens. , The ... Training , examined data relating to adolescents 13-19 years ...
    Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3
    ... on junk foods shown on television poses a real ... them to go for it thereby leading to overweight ... studies have already associated childhood overweight with television viewing, ... childhood overweight and TV viewing is due to children’s ...
    ... starting from Monday, to encourage the dropouts back to school, ... ,'The Rajya Shiksha Kendra (state education centre) will start ... bring all in the five to 14 years' age group ... said. ,'For the first time, staff from ...
    ... India firmly establishing itself as a medical tourism destination, ... only upmarket hotels// - travel desks, multi-cuisine menus, translators ... one of the prime requirements of a hospital servicing ... hospital here. ,With the Indian medical ...
    ... that alcoholics who are alone and suffer from alcohol-use disorders ... great// impact of personality disorders (PDs) on suicide attempt. ... patients who seek treatment for AUDs reports to have attempted ... the general population. The results were published in the journal ...
    ... The mystery surrounding a rare bone disease called fibrodysplasia ... of a mutant gene// linked to the disease. It ... second skeleton, making movement impossible. Nearly 2500 individuals are ... ,As the disease progresses, the muscles, ligaments, tendons, ...
    ... is commonly called, is a tropical disease that kills nearly ... able to put an end to this deadly killer, say ... would protect humans and animals. ,The disease is ... The spleen is the organ to be first affected ...
    Cached Medicine News:Health News:Junk Food Ads: The Culprit Behind Childhood Obesity 2Health News:World-class Facility A Must To Boost Medical Tourism In India 2Health News:Rare Bone Disease Traced To Faulty FOP Gene 2Health News:Researchers Hopeful About Vaccine For Leishmaniasis 2
    Indications For Usage: , ,For use during pulmonary lung function testing...
    ... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
    circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
    ... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
    Medicine Products: